291 related articles for article (PubMed ID: 37674786)
1. Endothelial Glycocalyx Injury in SARS-CoV-2 Infection: Molecular Mechanisms and Potential Targeted Therapy.
Lv B; Huang S; Huang H; Niu N; Liu J
Mediators Inflamm; 2023; 2023():6685251. PubMed ID: 37674786
[TBL] [Abstract][Full Text] [Related]
2. Endothelial glycocalyx shields the interaction of SARS-CoV-2 spike protein with ACE2 receptors.
Targosz-Korecka M; Kubisiak A; Kloska D; Kopacz A; Grochot-Przeczek A; Szymonski M
Sci Rep; 2021 Jun; 11(1):12157. PubMed ID: 34108510
[TBL] [Abstract][Full Text] [Related]
3. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.
Potje SR; Costa TJ; Fraga-Silva TFC; Martins RB; Benatti MN; Almado CEL; de Sá KSG; Bonato VLD; Arruda E; Louzada-Junior P; Oliveira RDR; Zamboni DS; Becari C; Auxiliadora-Martins M; Tostes RC
Life Sci; 2021 Jul; 276():119376. PubMed ID: 33781826
[TBL] [Abstract][Full Text] [Related]
4. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.
Nascimento Conde J; Schutt WR; Gorbunova EE; Mackow ER
mBio; 2020 Dec; 11(6):. PubMed ID: 33310781
[TBL] [Abstract][Full Text] [Related]
5. Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19).
Norooznezhad AH; Mansouri K
Microvasc Res; 2021 Sep; 137():104188. PubMed ID: 34022205
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Hu Y; Liu L; Lu X
Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
[TBL] [Abstract][Full Text] [Related]
7. Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection.
Gao X; Zhang S; Gou J; Wen Y; Fan L; Zhou J; Zhou G; Xu G; Zhang Z
J Infect; 2022 Oct; 85(4):418-427. PubMed ID: 35793758
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.
Xu B; Li G; Guo J; Ikezoe T; Kasirajan K; Zhao S; Dalman RL
J Vasc Surg; 2021 Nov; 74(5):1740-1751. PubMed ID: 33600934
[TBL] [Abstract][Full Text] [Related]
9. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection.
Beyerstedt S; Casaro EB; Rangel ÉB
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):905-919. PubMed ID: 33389262
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
11. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
13. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.
Ni W; Yang X; Yang D; Bao J; Li R; Xiao Y; Hou C; Wang H; Liu J; Yang D; Xu Y; Cao Z; Gao Z
Crit Care; 2020 Jul; 24(1):422. PubMed ID: 32660650
[TBL] [Abstract][Full Text] [Related]
14. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19.
Yamaoka-Tojo M
Biomed J; 2020 Oct; 43(5):399-413. PubMed ID: 33032965
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis.
Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF
Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423
[TBL] [Abstract][Full Text] [Related]
16. A human pluripotent stem cell-based model of SARS-CoV-2 infection reveals an ACE2-independent inflammatory activation of vascular endothelial cells through TLR4.
Ma Z; Li X; Fan RLY; Yang KY; Ng CSH; Lau RWH; Wong RHL; Ng KK; Wang CC; Ye P; Fu Z; Chin AWH; Lai MYA; Huang Y; Tian XY; Poon LLM; Lui KO
Stem Cell Reports; 2022 Mar; 17(3):538-555. PubMed ID: 35180397
[TBL] [Abstract][Full Text] [Related]
17. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
18. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.
Verma D; Church TM; Swaminathan S
J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.
Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
